Oxford Biomedica (LON:OXB) Given Hold Rating at Deutsche Bank Aktiengesellschaft

Oxford Biomedica (LON:OXB)‘s stock had its “hold” rating reiterated by Deutsche Bank Aktiengesellschaft in a research note issued to investors on Wednesday, Digital Look reports. They currently have a GBX 595 price objective on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target would indicate a potential upside of 36.63% from the stock’s current price.

A number of other analysts have also issued reports on OXB. Jefferies Financial Group reissued a “buy” rating and issued a GBX 8.27 target price on shares of Oxford Biomedica in a research report on Tuesday, June 2nd. Royal Bank Of Canada lowered their price target on Oxford Biomedica from GBX 1,140 to GBX 900 and set an “outperform” rating for the company in a research report on Monday, August 10th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of GBX 580.85.

Oxford Biomedica Price Performance

Oxford Biomedica stock opened at GBX 435.49 on Wednesday. The company’s 50 day simple moving average is GBX 566.92 and its 200-day simple moving average is GBX 606.44. The company has a debt-to-equity ratio of 162.16, a quick ratio of 1.67 and a current ratio of 2.20. Oxford Biomedica has a 1 year low of GBX 427 and a 1 year high of GBX 952. The company has a market capitalization of £527.10 million, a price-to-earnings ratio of -16.18 and a beta of 1.10.

Oxford Biomedica Company Profile

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.